Intra-Cellular price target raised to $119 from $113 at Canaccord

Canaccord raised the firm’s price target on Intra-Cellular (ITCI) to $119 from $113 and keeps a Buy rating on the shares. The firm said they are encouraged by continued solid execution and another beat-and-raise on Caplyta in a quarter that typically suffers from seasonality for this class of product.